<DOC>
	<DOCNO>NCT00140192</DOCNO>
	<brief_summary>Creatine play pivotal role brain energy homeostasis . Creatine supplementation widely use enhance sport performance , try treatment neurological , neuromuscular atherosclerotic disease paucity side effect . Dechent et al ( 1999 ) study effect oral creatine supplementation 4 wk demonstrate statistically significant increase mean concentration total creatine across brain region . These finding suggest possibility use oral creatine supplementation modify brain high-energy phosphate metabolism subject various brain disorder , include schizophrenia major depression . Recently , Rae et al ( 2003 ) report creatine supplementation 6 week significant positive effect work memory Raven matrix . Several independent line evidence suggest possible involvement alter cerebral energy metabolism schizophrenia . We perform double blind cross-over study creatine schizophrenia . Forty patient treat creatine 3 month double-blind crossover design . Rating scale include scale assess negative positive symptom schizophrenia , clinical global impression scale , scale side-effects cognitive battery Creatine effect brain energy metabolism possible cognitive enhancing property raise possibility develop new therapeutic strategy schizophrenia focus treat metabolic hypoactive brain area include frontal region .</brief_summary>
	<brief_title>Creatine Treatment Psychiatric Disorders</brief_title>
	<detailed_description>Creatine play pivotal role brain energy homeostasis , temporal spatial buffer cytosolic mitochondrial pool cellular energy currency adenosine triphosphate ( Wyss &amp; Kaddurah-Daouk , 2000 ) . Recent study suggest increased brain utilization oxygen follow oral creatine supplementation ( Persky &amp; Brazeua , 2001 ) . Creatine supplementation widely use enhance sport performance , try treatment neurological , neuromuscular atherosclerotic disease paucity side effect ( Persky &amp; Brazeua , 2001 ) . Creatine enters brain via specialized sodium dependent transporter . Dechent et al ( 1999 ) study effect oral creatine supplementation 20g/day 4 wk demonstrate significant increase mean concentration total creatine across brain region ( 8.7 % correspond 0.6mM , P &lt; 0.001 ) . Lyoo et al ( 2003 ) study magnetic resonance spectroscopy high-energy phosphate metabolite human brain follow oral supplementation creatine reporting creatine ( 0.3 g/kg/day first 7 day 0.03 g/kg/day next 7 day ) significantly increase brain creatine level . These finding suggest possibility use oral creatine supplementation modify brain high-energy phosphate metabolism subject various brain disorder , include schizophrenia major depression , alteration brain high-energy phosphate metabolism report . Kieburtz et al ( see : http : //www.huntington-study-group.org/Creatine % 20abstract.htm ) conduct double blind clinical trial creatine 50 ambulatory Huntington disease subject randomize creatine placebo . Those randomized creatine receive 3g 2 month 5g additional 2 month . There significant adverse event associate creatine significant change laboratory test vital sign . In creatine treat group creatine plasma level approximately double ( 210 ± 335 µM vs. 500 ± 125 µM ) . Kieburtz et al currently also conduct multi-center , double-blind study creatine patient Parkinson 's disease , fund National Institute Neurological Disorders Stroke ( NINDS ) . Recently , Rae et al ( 2003 ) report creatine supplementation ( 5 gram per day 6 week ) significant positive effect ( p &lt; 0.0001 ) work memory ( backward digit span ) Raven 's Advanced Progressive Matrices . These finding suggest role brain energy capacity influence brain cognitive performance creatine via effect brain energy metabolism may exert beneficial effect cognition . Several independent line evidence suggest possible involvement alter cerebral energy metabolism pathophysiology schizophrenia . Imaging study use positron emission tomography ( PET ) flurodeoxyglucose ( FDG ) , functional magnetic resonance imaging ( fMRI ) , 15O magnetic resonance spectroscopy 31P ( 31P-MRS ) single photon emission tomography ( SPECT ) , investigate cerebral metabolic rate schizophrenia . Most study reveal decreased metabolism frontal cortex schizophrenia , term hypofrontality . Several study also observe alteration brain metabolic rate brain region include temporal lobe , thalamus basal ganglion , lead suggestion impairment fronto-striatal-thalamic circuitry schizophrenia rather specific brain region ( Andreasen et al . 1997 ) . A direct link phosphocreatine ATP energy system come study use 31P-MRS without chemical shift imaging , enable measurement ATP , phosphocreatine inorganic phosphate . These study show reduced ATP frontal lobe leave temporal lobe schizophrenic patient compare control ( Volz et al . 2000 ) . Altered brain energy metabolism could due impairment mitochondrion variety study review recently Ben Shachar ( 2002 ) suggest impaired mitochondrial energy metabolism schizophrenia . Interestingly , creatine besides energy sparing property also show neuroprotective property variety animal model brain disease include Huntington Parkinson diseases , well exert protective effect animal model cerebral hypoxia ( Persky &amp; Brazeua , 2001 ) . We perform double blind cross-over study creatine schizophrenia . Forty consent schizophrenic patient , 18-60 year old , physically healthy , 2 year illness stable condition ( gross change clinical presentation last 6 month judge patient 's psychiatrist ) present negative cognitive symptom ( judged patient 's psychiatrist along score least 3 item PANSS negative subscale =4 point , item PANSS positive subscale score = 3 point ) . These patient recruit study two year . Excluded patient alcohol drug abuse 6 month prior entry study clinically significant medical condition laboratory abnormality . Twenty patient treat creatine 3 month ( 3 g daily first month 5 g daily another 2 month ) 3 month placebo . The twenty patient administer placebo 3 month creatine 3 month dosages procedure . Patients ' neuroleptic treatment affect study participation . Mood stabilizer , benzodiazepine anticholinergic medication allow dos document throughout study . Routine blood test include kidney function , liver function well plasma creatine creatinine monitor baseline monthly throughout study . Positive Negative Syndrome Scale ( PANSS ) , Clinical Global Impressions ( CGI ) , Adverse effect/side effect assessment administer baseline monthly . A Cognitive Battery administer baseline , three month , six month consist California Verbal Learning Test ; Trail make A &amp; B ; Purdue Pegboard ; Digit Symbol Coding ; Continuous performance test ; Reaction Time performance Test Wisconsin Card Sort Test . Power Analysis : We demonstrate significant effect add-on schizophrenia design folate treatment homocysteine lower strategy schizophrenia . A sample 36 subject recruit 24 month show statistically significant , clinically relevant difference active treatment placebo similar design propose . Creatine administration safe paucity side effect . Creatine effect brain energy metabolism possible cognitive enhancing property raise possibility develop new therapeutic strategy schizophrenia focus treat metabolic energetic hypoactive brain area include frontal region . My personal research experience position Beersheva Mental Health Centre make trial eminently feasible . REFERENCES Andreasen NC , O'Leary DS , Flaum M , Nopoulos P , Watkins GL , Boles Ponto LL , et al . Hypofrontality schizophrenia : distribute dysfunctional circuit neuroleptic-naive patient . Lancet 1997 ; 349 : 1730-4 . Ben-Shachar D. Mitochondrial dysfunction schizophrenia : possible linkage dopamine . J Neurochem 2002 ; 83 : 1241-51 . Dechent P , Pouwels PJ , Wilken B , Hanefeld F , Frahm J . Increase total creatine human brain oral supplementation creatine-monohydrate . Am J Physiol 1999 ; 277 : R698-704 . Lyoo IK , Kong SW , Sung SM , Hirashima F , Parow A , Hennen J , et al . Multinuclear magnetic resonance spectroscopy high-energy phosphate metabolite human brain follow oral supplementation creatine-monohydrate . Psychiatry Res 2003 ; 123 : 87-100 . Persky AM , Brazeau GA. Clinical pharmacology dietary supplement creatine monohydrate . Pharmacol Rev 2001 ; 53 : 161-76 . Rae C , Digney AL , McEwan SR , Bates TC . Oral creatine monohydrate supplementation improve brain performance : double-blind , placebo-controlled , cross-over trial . Proc R Soc Lond B Biol Sci 2003 ; 270 : 2147-50 . Volz H , Gaser C , Sauer H. Supporting evidence model cognitive dysmetria schizophrenia -- structural magnetic resonance imaging study use deformation-based morphometry . Schizophr Res 2000 ; 46 : 45-56 . Wyss M , Kaddurah-Daouk R. Creatine creatinine metabolism . Physiol Rev 2000 ; 80 : 1107-213 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>age 1860 physically healthy least 2 year illness stable condition present negative cognitive symptom drug alcohol abuse clinically significant medical condition laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>creatine metabolism</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>energy metabolism</keyword>
</DOC>